Panion & Bf Biotech Inc.

Total Valuation

Panion & Bf Biotech Inc. carries a market capitalization of 5.24B, placing it among publicly traded companies globally. Its enterprise value stands at 5.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Panion & Bf Biotech Inc. currently has 85.74M shares outstanding.

Valuation Ratios

Panion & Bf Biotech Inc. trades at a trailing price-to-earnings ratio of 28.46. The price-to-sales ratio is 2.62, and the price-to-book ratio stands at 5.14.

Enterprise Valuation

On an enterprise value basis, Panion & Bf Biotech Inc. trades at an EV/EBITDA multiple of 18.14 and an EV/FCF ratio of 11.99. The EV/Sales ratio of 2.71 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.14 provides insight into valuation relative to core operating earnings.

Financial Position

Panion & Bf Biotech Inc. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.14, indicating elevated leverage, while an interest coverage ratio of 21.52 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Panion & Bf Biotech Inc. posts a return on equity of 18.59 and a return on invested capital of 7.63.

Taxes

Over the trailing twelve months, Panion & Bf Biotech Inc. has paid 103.87M in income taxes, reflecting an effective tax rate of 35.32.

Stock Price Statistics

Panion & Bf Biotech Inc.'s stock has declined approximately -25.75942% over the past 52 weeks. The 50-day moving average sits at 63.43, while the 200-day moving average is 65.08.

Income Statement

Over the trailing twelve months, Panion & Bf Biotech Inc. generated 2.06B in revenue and converted that into 190.17M in net income, yielding earnings per share of 2.21. EBITDA reached 308.70M, while operating income came in at 308.70M.

Balance Sheet

Panion & Bf Biotech Inc. holds 460.32M in cash and equivalents against 647.70M in total debt, resulting in a net debt position of 139.83M. Total book value stands at 1.05B, with working capital of 457.05M providing operational flexibility.

Cash Flow

Panion & Bf Biotech Inc. produced 309.57M in operating cash flow over the past twelve months. After subtracting -148.34M in capital expenditures, free cash flow totaled 161.23M - equivalent to 1.88 per share.

Margins

Panion & Bf Biotech Inc. operates with a gross margin of 54.13, reflecting its pricing power and cost economics. The operating margin of 14.96 and net profit margin of 9.22 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Panion & Bf Biotech Inc.'s most recent stock split took place on August 6, 2021 with a 500:507 split ratio.

Scores

Panion & Bf Biotech Inc. posts an Altman Z-Score of 3.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.